MIT researchers have developed a new method for designing 3D structures that can be transformed from a flat configuration ...

In a new paper from OpenAI, the company proposes a framework for analyzing AI systems' chain-of-thought reasoning to understand how, when, and why they misbehave.

Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic ...

Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

In a recent study, mathematicians from Freie Universität Berlin have demonstrated that planar tiling, or tessellation, is much more than a way to create a pretty pattern. Consisting of a surface ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...